Founded in 2002, AccessClosure is a privately held medical device company that is pioneering innovative access site management products designed to address the complex challenge of vascular closure during interventional and diagnostic procedures.
Our first product, the Mynx vascular closure device, is based on a conformable, water soluble polyethylene glycol (PEG) sealant that instantly expands in the tissue tract by rapidly absorbing blood and subcutaneous fluids. The sealant then dissolves within 30 days, leaving nothing behind but a healed artery.
Mynx has been authorized for CE Mark and received FDA approval on May 16, 2007.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 12/31/07 | Series B | 35M | Accel Partners, New Leaf Venture Partners, Onset Ventures, Three Arch Partners | Unknown |
People
Mike MacKinnon (VP Sales)
Rhonda Coulston (Director of Human Resources)
John Buckley (CFO)
Laura Cox (Sr. Director of Marketing)
Jon Bohane (VP Finance)
Competitors
HyperBranch Medical Technology:
HyperBranch Medical Technology is a biosurgical device company focused on the design, development, and manufacture of… See Company Profile »
News
Access Closure nabs $10M for wound-sealing device
March 3, 2010 6:31 pm
July 9-10, 2013 San Francisco, CA Tickets On Sale Now Access Closure, maker of a device that helps close wounds… Continue reading ⟩